GeoVax's Multi-Antigen COVID Vaccine Shows Strong Results in High-Risk Patients
September 12, 2025 — GeoVax's GEO-CM04S1 COVID-19 vaccine shows strong immune responses in immunocompromised patients, outperforming mRNA vaccines in Phase 2 trials with no serious adverse events.